A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function

Trial Profile

A Multi-center, Open Label Study to Assess Pharmacokinetics of TKI258 in Adult Cancer Patients With Normal and Impaired Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 05 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 May 2014 Planned number of patients changed from 30 to 65 as reported by ClinicalTrials.gov..
    • 18 Oct 2013 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top